Selected article for: "admission lymphocyte count and low lymphocyte"

Author: Chen, Wanxin; Li, Ziping; Yang, Bohan; Wang, Ping; Zhou, Qiong; Zhang, Zhiguo; Zhu, Jianhua; Chen, Xuexing; Yang, Peng; Zhou, Hao
Title: Delayed‐Phase Thrombocytopenia in Patients of Coronavirus Disease 2019 (COVID‐19)
  • Cord-id: vknxzzgm
  • Document date: 2020_5_26
  • ID: vknxzzgm
    Snippet: COVID‐19 can affect the hematopoietic system. Thrombocytopenia at admission was prevalent, while late‐phase or delayed‐phase thrombocytopenia (occurred 14 days after symptom onset) is obscure. This retrospective single‐center study screened 450 COVID‐19 patients and enrolled 271 patients at the Union Hospital, Wuhan, China, from January 25th to March 9th, 2020. COVID‐19 associated delayed‐phase thrombocytopenia occurred in 11.8% percent of enrolling patients. The delayed‐phase th
    Document: COVID‐19 can affect the hematopoietic system. Thrombocytopenia at admission was prevalent, while late‐phase or delayed‐phase thrombocytopenia (occurred 14 days after symptom onset) is obscure. This retrospective single‐center study screened 450 COVID‐19 patients and enrolled 271 patients at the Union Hospital, Wuhan, China, from January 25th to March 9th, 2020. COVID‐19 associated delayed‐phase thrombocytopenia occurred in 11.8% percent of enrolling patients. The delayed‐phase thrombocytopenia in COVID‐19 is prone to develop in elderly patients or patients with low lymphocyte count on admission. The delayed‐phase thrombocytopenia is significantly associated with increased length of hospital stay and higher mortality rate. Delayed‐phase nadir platelet counts demonstrated a significantly negative correlation with B cell percentages. We also presented bone marrow aspiration pathology of three patients with delayed‐phase thrombocytopenia, showing impaired maturation of megakaryocytes. We speculated that immune mediated platelet destruction might account for the delayed‐phase thrombocytopenia in a group of patients. Besides, clinicians need to pay attention to the delayed‐phase thrombocytopenia especially at 3‐4 weeks after symptom onset.

    Search related documents:
    Co phrase search for related documents
    • accepted article and longitudinal study: 1
    • active player and lymphocyte subset: 1
    • acute respiratory syndrome and admission lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low admission lymphocyte count: 1
    • acute respiratory syndrome and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute respiratory syndrome and lung addition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung sars major target: 1
    • acute respiratory syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymphocyte subset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and lymphocyte subset cytokine: 1
    • admission lymphocyte count and low admission lymphocyte count: 1, 2, 3, 4
    • admission lymphocyte count and low lymphocyte count: 1, 2, 3, 4, 5, 6
    • admission lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission lymphocyte count and lymphocyte subset: 1
    • admission time and longitudinal study: 1, 2, 3, 4, 5, 6
    • admission time and low lymphocyte count: 1, 2, 3, 4, 5, 6
    • admission time and lung addition: 1, 2, 3